Ioglicic acid
 | |
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID |
|
| DrugBank |
|
| ChemSpider |
|
| UNII |
|
| KEGG |
|
| ChEMBL |
|
| CompTox Dashboard (EPA) |
|
| ECHA InfoCard | 100.051.320 |
| Chemical and physical data | |
| Formula | C13H12I3N3O5 |
| Molar mass | 670.968 g·mol−1 |
| 3D model (JSmol) |
|
| |
Ioglicic acid is a pharmaceutical drug that was used as an iodinated contrast medium for X-ray imaging, in form of its salt meglumine ioglicate. Uses included imaging of the brain,[1] the aorta and femoral arteries,[2] and the urinary system (an examination called intravenous urography).[3]
It is not known to be marketed anywhere in the world in 2021.
References
- ^ Skalpe IO (1983). "Enhancement with water-soluble contrast media in computed tomography of the brain and abdomen. Survey and present state". Acta Radiologica. Supplementum. 366: 72–5. PMID 6382938.
- ^ Wiebe V, Straub H (1983). "Haemodynamic side effects of meglumine ioglicate, meglumine sodium ioxaglate and iohexol in aortofemoral angiography: comparison of a high-osmolar and two low-osmolar radiological contrast media". Fortschritte Auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. Erganzungsband. 118: 78–84. PMID 6139084.
- ^ Baitsch T, Beduhn D, Klink G (1983). "Double blind comparison of ioglicate and iothalamate in intravenous urography". Fortschritte Auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. Erganzungsband. 118: 143–7. PMID 6139069.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |